Arctic Therapeutics Announces Enrollment of First Patients in Phase IIa Trial of AT-004 for Acne Vulgaris

Arctic Therapeutics Iceland

Acne vulgaris affects an estimated 650 million people worldwide with a significant impact on quality of life, mental well-being, and self-esteem.AT-004 targets a novel, TNF-?-modulating anti-inflammatory pathway in the skin, with relevance across multiple inflammatory dermatologic conditions.View original content:https://www.prnewswire.co.uk/news-releases/arctic-therapeutics-announces-enrollment-of-first-patients-in-phase-iia-trial-of-at-004-for-acne-vulgaris-302684721.html